CLOs on the Move

Scientia Vascular

www.scientiavascular.com

 
Scientia Vascular offers access devices (microcatheters / guidewires) and therapies that are optimized to address the evolving needs of interventional specialists. Learn more about our next-generation solutions.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Fleming Pharmaceuticals

Fleming Pharmaceuticals is a Fenton, MO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Premier Research

Premier Research is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.

Stayma Consulting Services

Stayma Consulting Services is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix`s proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.